Quantum Genomics Société Anonyme
Save
6.93M
Market cap
Current P/E
Forward P/E

About

Health care
Sector
Biotechnology
Industry

Quantum Genomics Société Anonyme, a biopharmaceutical company, develops drugs to treat cardiovascular diseases. It develops drugs based on brain aminopeptidase A inhibition (BAPAI) platform primarily to treat high blood pressure and heart failure. The company develops firibastat, a monotherapy drug that is in pivotal Phase III study for the treatment of hypertension, as well as in clinical trial for the treatment of heart failure.

Similar securities

Based on sector and market capitalization

Report issue